Goldman Sachs
AEGR

Goldman Sachs’s Aegerion Pharmaceuticals AEGR Stock Holding History

Goldman Sachs’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-45,000
Closed -$612K – 7550
2015
Q3 		$612K Buy
+45,000
New +$801K ﹤0.01% 4944
2015
Q1 		– Sell
-916,600
Closed -$19.2M – 7455
2014
Q4 		$19.2M Buy
916,600
+335,200
+58% +$8.45M 0.01% 1849
2014
Q3 		$19.4M Buy
581,400
+551,400
+1,838% +$17.1M 0.01% 1803
2014
Q2 		$963K Sell
30,000
-606,100
-95% -$22.6M ﹤0.01% 4719
2014
Q1 		$29.4M Buy
636,100
+151,400
+31% +$8.88M 0.01% 1453
2013
Q4 		$34.4M Buy
+484,700
New +$37.1M 0.01% 1337

Goldman Sachs's AEGR Position: Q4 2016 in Review

Goldman Sachs sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 218,481 shares — an estimated $649K sold.

Goldman Sachs first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $18.6M in Q4 2014. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.

  • Goldman Sachs reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Goldman Sachs sold 218,481 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $649K.
  • Goldman Sachs first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
  • Goldman Sachs's Aegerion Pharmaceuticals position peaked at $18.6M in Q4 2014.
  • 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.

Based on Goldman Sachs's 13F filing for Q4 2016, filed 14 Feb 2017.